Company to Webcast Presentation on February 9
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company
focused on discovering, developing, and commercializing small molecule
drugs to treat severe medical conditions, today announced that the
Company will be presenting at the BIO CEO & Investor Conference on
Monday, February 9, 2009 at 3:15 pm (ET) at the Waldorf Astoria Hotel in
In addition, Safi Bahcall, Ph.D., President and CEO, Synta
Pharmaceuticals will be a panelist in the BIO CEO therapeutic workshop Oncology:
The Forecast for the Melanoma Market—Partly Sunny or Mostly Cloudy?
at 12:30 pm (ET) on Tuesday, February 10. Dr. Bahcall will discuss
oxidative stress induction as a new therapeutic approach to treating
melanoma and other cancers.
A live audio webcast and replay of the presentation will be available on
the "Investors" section of the Company's website, www.syntapharma.com.
The panel will not be webcast.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to
extend and enhance the lives of patients with severe medical conditions,
including cancer and chronic inflammatory diseases. Synta has a unique
chemical compound library, an integrated discovery engine, and a diverse
pipeline of clinical- and preclinical-stage drug candidates with
distinct mechanisms of action and novel chemical structures. All Synta
drug candidates were invented by Synta scientists using our compound
library and discovery capabilities. Synta has a partnership with
GlaxoSmithKline for the joint development and commercialization of its
lead investigational drug candidate, elesclomol, which is in a global,
pivotal Phase 3 clinical trial for the treatment of metastatic melanoma.
For more information, please visit www.syntapharma.com.
Source: Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp.
Rob Kloppenburg, 781-541-7125
Doug MacDougall, 781-235-3060